SAM
LENZ

Smartleaf Asset Management’s LENZ Therapeutics LENZ Stock Holding History

Smartleaf Asset Management’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$307 Sell
37
-152
-80% -$2.13K ﹤0.01% 3290
2025
Q4 		$3.05K Buy
189
+178
+1,618% +$5.19K ﹤0.01% 2859
2025
Q3 		$493 Buy
+11
New +$404 ﹤0.01% 2858
2025
Q2 		– Sell
-11
Closed -$282 – 2995
2025
Q1 		$282 Hold
11
– – ﹤0.01% 2765
2024
Q4 		$330 Hold
11
– – ﹤0.01% 2832
2024
Q3 		$264 Hold
11
– – ﹤0.01% 2851
2024
Q2 		$195 Buy
+11
New +$192 ﹤0.01% 2681

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Smartleaf Asset Management's LENZ Position: Q1 2026 in Review

Smartleaf Asset Management reduced its LENZ Therapeutics (LENZ) stake by 80% in Q1 2026, selling an estimated $2.13K and leaving 37 shares worth $307. The position accounts for ﹤0.01% of the portfolio, ranked #3290.

Smartleaf Asset Management first reported a position in LENZ in Q2 2024 and has held it in 7 quarters since. The position peaked at $3.05K in Q4 2025. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

  • Smartleaf Asset Management held 37 shares of LENZ Therapeutics worth $307 as of Q1 2026.
  • Smartleaf Asset Management sold 152 LENZ Therapeutics shares in Q1 2026, an estimated $2.13K.
  • LENZ Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q1 2026, its #3290 holding.
  • Smartleaf Asset Management first reported a position in LENZ Therapeutics in Q2 2024 and has held it in 7 quarters since.
  • Smartleaf Asset Management's LENZ Therapeutics position peaked at $3.05K in Q4 2025.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on Smartleaf Asset Management's 13F filing for Q1 2026, filed 15 May 2026.